Biogen Inc (BUE:BIIB)

ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 27.95 PB Ratio: 2.13 GF Score: 49/100

Biogen Inc Aducanumab Phase 3 Topline Results Transcript

Apr 02, 2020 / 10:00PM GMT

Release Date Price: ARS2081.5

Transcript

Samantha Budd Haeberlein

Biogen Inc. - VP of Clinical Development

All right. Good morning. My name is Samantha Budd Haeberlein. And on behalf of my co-authors here, I would like to present the EMERGE and ENGAGE top line results. These were 2 identically designed Phase III studies to evaluate the effectiveness of aducanumab in patients with early Alzheimer's disease.

Here are the disclosure of the authors. And I would like to remind you that aducanumab is an investigational compound and is not yet approved in any country. The aducanumab Phase III studies called EMERGE and ENGAGE were 2 18-month randomized, double-blind, placebo-controlled Phase III studies. They recruited 3,285 patients in 348 sites in 20 countries. The population that was enrolled in these studies was patients with MCI due to Alzheimer's disease and patients with mild Alzheimer's disease dementia with a baseline MMSE of 24 to 30 inclusive and a CDR of 0.5. There were 2 dosing regimens that were tested, a low and a high dose, and these were randomized 1:1:1 with placebo. The primary end point was the CDR sum of boxes changed from

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.